Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Signaling and Regulation

The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance

Natalia Filippova, Xiuhua Yang, Yimin Wang, G. Yancey Gillespie, Cathy Langford, Peter H. King, Crystal Wheeler and L. Burt Nabors
Natalia Filippova
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiuhua Yang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yimin Wang
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. Yancey Gillespie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cathy Langford
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter H. King
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Crystal Wheeler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Burt Nabors
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1541-7786.MCR-10-0325 Published May 2011
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    Silencing of HuR alters glioma growth and sensitizes cells to chemotherapeutic induction of apoptosis. A, the growth of U251 is constrained compared with controls over a 4-day time course. B, HuR silencing in U251 induces activation of the intrinsic pathway of apoptosis with cleavage of caspase-3 and PARP. The time course is after the addition of the siRNA oligos. C, colony formation in soft agar is markedly reduced for HuR knockdown compared with control. Quantitation of colony number in soft agar experiment is represented by the bar graph (*, P = 0.0016). D, the graph depicts a sensitization of glioma cell line to cytotoxic agents with HuR knockdown for common types of chemotherapy.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Inducible overexpression of HuR enhances bcl-2 expression and chemoresistance. A, the Flag-HuR inducible clones (n = 2) show a specific and marked increase in bcl-2 family interaction with HuR following induction (dox treated is normalized by the untreated) and immunoprecipitation with a control IgG or HuR antibody (experiment done in triplicate). The error bars represent standard deviation. An inset reveals robust expression of the Flag-tagged HuR with dox. B, the IC50 curves with standard cytotoxic agents in a cell viability assay show chemoresistance after the induction of HuR, a shift to the right is seen for all agents.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    A specific molecular interaction exist between HuR and the bcl-2 family RNA. A, lane 1 shows the UVX pattern of glioma protein extract and 32P-labeled riboprobes for the indicated bcl-2 member 3′-UTR; lane 2 is an IP of the UVX with a HuR Ab to define the HuR band; and lane 3 is a control IP with normal mouse IgG. A (right), UVX using 4 riboprobes representing various regions of the mcl-1 3′-UTR (Supplementary Table S1 for definition of regions). The UVX lanes are overexposed to better visualize the HuR IP in lane 2. B, qRT-PCR for the bcl-2 family from total RNA isolated by HuR IP confirms an interaction. The bcl-2 family can be quantified from HuR IP compared with the control IP with IgG. C, a schematic illustrating the location of riboprobes (P) relative to bcl-2 family 3′-UTR and the open reading frame.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    The knockdown of HuR primarily effects the degradation kinetics of the bcl-2 family. A, a significant difference was not noted in RNA expression levels for the bcl-2 family following knockdown with shHuR or shControl (replicates of 3 for 2 shHuR clones and 6 for single shControl clone). B, the degradation kinetics of the bcl-2 family was markedly reduced after silencing for HuR (replicates of 3)

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Impact of HuR knockdown on bcl-2 family RNA distribution within the polyribosome and protein expression. A, the silencing of HuR in multiple clones with the concurrent reduction in protein expression of all bcl-2 family members in select clones (*) which were used for phenotypic studies. Band density was normalized to tubulin and then compared with U251 to generate percent expression (shown below the blot). B, Western blot analysis from protein samples of 12 fractions collected following polyribosome isolation. S6 and elf4E are ribosomal components and used for control. HuR is reduced in the polysome fractions of shHuR cells compared with controls. C, the quantitation of RNA from each fraction for GAPDH and the bcl-2 family. Overall, the patterns differ depending on the target with a slight increase in distribution to later fractions (8–12) following HuR knockdown. The data are presented so that each bar represents the percentage of RNA from that fraction divided by the total for all 12 fractions.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    Lentivirus-mediated HuR silencing in established and primary GBM lines. A, fluorescent microscopy showing robust infectivity of control (V-GFP) and 3 shHuR GFP-lentiviral constructs (V1–3-shHuR) in U251. B, the lentivirus constructs robustly knockdown HuR. B, the quantitation of HuR RNA levels by TaqMan and a following Western blot show effective knockdown of HuR with each of the shHuR lentiviruses (V1–3) but not with control (V-GFP). The most consistent and robust was V2, which was carried forward in animal experiments. C, the 4 primary GBM lines available are shown in phase contrast (top) and after transduction with the GFP lentivirus (bottom). D, all lines were uniformly infected with 100% cellular transduction by 20 viral units per cell. E, Western blotting of protein extracts from D456 confirms knockdown of HuR in V2shHuR cells compared with shControl. Similar results were seen for the other primary GBM lines.

  • Figure 7.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 7.

    The GFP marker in the lentivirus facilitates in vivo assessment of GBM growth. A, whole brain dissection after sacrifice showing extensive and bilateral green fluorescence in the shControl mouse versus limited signal in the shHuR mouse. B, a background coronal section is shown at the top followed by a GFP image and then a subtraction. The subtraction allows for quantification of tumor volume and extent of infiltration and confirms the extensive growth and infiltration of the shControl-infected cells.

  • Figure 8.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 8.

    HuR knockdown reduces GBM tumor growth in vivo. A, coronal sections of mouse brains injected with shControl or V2shHuR-infected D456 GBM cells are shown. V2shHuR cells produced a smaller and less infiltrative tumor compared with shControl (arrows). B, representative tumor sections immunostained for HuR (red) and counterstained with DAPI (blue) showing reduced expression of HuR in the V2shHuR-infected GBM cells.

Tables

  • Figures
  • Additional Files
  • Table 1.

    Data for the 3 sets of animal experiments with each primary GBM line

    Primary GBM lineshControlMiceSEMshHuRMiceSEMP
    Primary endpoint is tumor area mm2
    D456985116251.50.0116
    GBM1231581254.70.10
    GBM61.050.060.0450.020.0001
    Primary endpoint is number of distinct tumor foci
    GBM641592.4540.0002

    NOTE: When tumor size is the primary endpoint, a consistent size difference is seen following silencing of HuR (shHuR). GBM6 shows a very migratory behavior and a difference in tumor foci is quantified as a second primary endpoint.

    Additional Files

    • Figures
    • Tables
    • Supplementary Data

      Supplementary Figures S1-S2.

      Files in this Data Supplement:

      • Supplementary Figures S1-S2
    PreviousNext
    Back to top
    Molecular Cancer Research: 9 (5)
    May 2011
    Volume 9, Issue 5
    • Table of Contents
    • About the Cover

    Sign up for alerts

    View this article with LENS

    Open full page PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for sharing this Molecular Cancer Research article.

    NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

    Enter multiple addresses on separate lines or separate them with commas.
    The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance
    (Your Name) has forwarded a page to you from Molecular Cancer Research
    (Your Name) thought you would be interested in this article in Molecular Cancer Research.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance
    Natalia Filippova, Xiuhua Yang, Yimin Wang, G. Yancey Gillespie, Cathy Langford, Peter H. King, Crystal Wheeler and L. Burt Nabors
    Mol Cancer Res May 1 2011 (9) (5) 648-659; DOI: 10.1158/1541-7786.MCR-10-0325

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    The RNA-Binding Protein HuR Promotes Glioma Growth and Treatment Resistance
    Natalia Filippova, Xiuhua Yang, Yimin Wang, G. Yancey Gillespie, Cathy Langford, Peter H. King, Crystal Wheeler and L. Burt Nabors
    Mol Cancer Res May 1 2011 (9) (5) 648-659; DOI: 10.1158/1541-7786.MCR-10-0325
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • Introduction
      • Materials and Methods
      • Results
      • Discussion
      • Disclosure of Potential Conflicts of Interest
      • Grant Support
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • PDF
    Advertisement

    Related Articles

    Cited By...

    More in this TOC Section

    • Analysis of RAF-MEK-ERK Signaling in Pancreas Cancer
    • Wnt3 Promotes EMT and Acquired Resistance to Trastuzumab
    • Patched Functions in Multidrug Transport
    Show more Signaling and Regulation
    • Home
    • Alerts
    • Feedback
    • Privacy Policy
    Facebook  Twitter  LinkedIn  YouTube  RSS

    Articles

    • Online First
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts

    Information for

    • Authors
    • Subscribers
    • Advertisers
    • Librarians

    About MCR

    • About the Journal
    • Editorial Board
    • Permissions
    • Submit a Manuscript
    AACR logo

    Copyright © 2021 by the American Association for Cancer Research.

    Molecular Cancer Research
    eISSN: 1557-3125
    ISSN: 1541-7786

    Advertisement